United Therapeutics Income Statement
UTHR / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
United Therapeutics reported $3.2B in revenue and $1.3B in net income for FY2025. Revenue has grown at a 16.9% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B | $1.5B | $1.4B | $1.6B | $1.5B | $1.6B | $1.5B | $1.3B | $1.1B | $592.9M | $358.9M |
| Cost of Revenue | $384.4M | $309.7M | $257.5M | $151.6M | $122.5M | $108.1M | $117.6M | $198.7M | $69.0M | $72.7M | $69.0M | $125.9M | $131.1M | $67.7M | $40.9M |
| Gross Profit | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B | $1.4B | $1.3B | $336.0M | $356.2M | $368.3M | $306.7M | $254.0M | $975.8M | $524.0M | $316.8M |
| SG&A Expense | $755.8M | $709.7M | $477.1M | $482.1M | $467.0M | - | - | $265.8M | $452.7M | $316.8M | $452.7M | $381.3M | $394.0M | $188.6M | $171.9M |
| R&D Expense | $550.0M | $481.0M | $408.0M | $322.9M | $540.1M | $357.7M | $1.2B | $357.9M | $245.1M | $147.6M | $245.1M | $242.5M | $299.3M | $165.3M | $120.4M |
| Operating Income | $1.5B | $1.4B | $1.2B | $979.7M | $555.9M | $593.6M | -$187.6M | $805.4M | $699.0M | $1.1B | $699.0M | $538.8M | $292.5M | $171.3M | $25.8M |
| Interest Expense | - | - | $59.3M | $32.4M | $18.6M | $23.5M | $44.2M | $13.9M | $4.7M | $3.9M | $4.7M | $17.6M | $18.1M | $19.7M | $12.9M |
| Income Tax | $379.2M | $343.9M | $289.5M | $223.3M | $118.1M | $124.1M | -$60.5M | $169.7M | $392.8M | $346.5M | $392.8M | $185.1M | $104.3M | $43.9M | -$695.0K |
| Net Income | $1.3B | $1.2B | $984.8M | $727.3M | $475.8M | - | -$104.5M | $589.2M | $651.6M | $713.7M | $651.6M | - | - | - | - |
| EPS (Basic) | $21.04 | $15.98 | $10.60 | $11.65 | -$2.39 | $13.54 | $9.50 | $16.29 | $14.17 | $7.06 | $3.49 | $5.84 | $3.81 | $1.89 | $0.37 |
| EPS (Diluted) | $19.81 | $15.00 | $10.06 | $11.54 | -$2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 | $0.35 |
| Shares Outstanding | 44.8M | 47.0M | 46.0M | 45.1M | 44.5M | 43.9M | 43.6M | 43.2M | 43.0M | 45.8M | 47.1M | 50.4M | 50.2M | 53.6M | 57.6M |
| Gross Margin | 87.9% | 89.2% | 88.9% | 92.2% | 92.7% | 92.7% | 91.9% | 20.6% | 24.3% | 23.0% | 20.9% | 19.7% | 87.4% | 88.4% | 88.3% |
| Operating Margin | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% | 40.0% | -13.0% | 49.5% | 47.7% | 66.4% | 47.7% | 41.8% | 26.2% | 28.9% | 7.2% |
| Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | - | -7.2% | 36.2% | 44.5% | 44.6% | 44.5% | - | - | - | - |